Cormorant Asset Management, LP
BOSTON, MA · CIK 1583977 · 13F filing filed 2022-08-15
SEC-registered investment adviser since 2014 · limited partnership
- Assets managed$3.8bn
- Staff12 · 3 in investment roles
- Main clients (by assets)Private funds 100%
- Private funds7 (1 hedge) · $3.8bn gross assets
- Form ADV · 2026-05-27SEC adviser record
- Legal entityCormorant Asset Management, LP (US)
- Kindhedge funds, private equity, futures
- Others nearbyBoston, MA
As an employer
- Offices in1 country
- Private fundshedge 1, private equity 6
$1.3bn
reported value
-1.0% vs Q1 2022
79positions
46.6%in top 10
8 new
15 added
15 reduced
6 sold out
vs Q1 2022
Options: 1 call positions ($33.4m notional), 0 put positions (— notional) – listed below, not included above.
This report includes the holdings of 1 other manager that shares the investment decisions:
- Chen Bihua – reports through this filing
Shares in two reports are counted once in each security's totals.
Holdings, Q2 2022
The small lines show how much was held over the last 4 quarters (adjusted for stock splits).
| Security | Value | Change |
|---|---|---|
| TURNING POINT THERAPEUTICS I COM | $186.9m14.50% | Reduced -1.2m |
| DESIGN THERAPEUTICS INC DSGN | $77.0m5.97% | Added +343.0k |
| ERASCA INC ERAS | $58.5m4.54% | Unchanged |
| PROMETHEUS BIOSCIENCES INC COM | $57.3m4.44% | Added +205.7k |
| APELLIS PHARMACEUTICALS INC APLS | $43.0m3.33% | Reduced -175.0k |
| REVOLUTION MEDICINES INC RVMD | $38.9m3.02% | Unchanged |
| BIOMEA FUSION INC BMEA | $38.0m2.95% | Unchanged |
| CHEMOCENTRYX INC CCXI | $35.3m2.74% | Added +560.0k |
| ALTIMMUNE INC ALT | $35.1m2.72% | New |
| MOONLAKE IMMUNOTHERAPEUTICS MLTX | $30.9m2.40% | New |
| EDGEWISE THERAPEUTICS INC EWTX | $30.6m2.38% | Reduced -832.9k |
| AVIDITY BIOSCIENCES INC RNA | $29.2m2.27% | Unchanged |
| MONTE ROSA THERAPEUTICS INC GLUE | $28.9m2.25% | Reduced -8.5k |
| ARCELLX INC ACLX | $27.6m2.14% | New |
| TARSUS PHARMACEUTICALS INC TARS | $27.4m2.12% | Added +499.0k |
| AEROVATE THERAPEUTICS INC COM | $27.1m2.10% | Reduced -100.0k |
| BIOHAVEN PHARMACTL HLDG CO L BHVN | $26.9m2.09% | Added +104.9k |
| ADICET BIO INC COM | $26.3m2.04% | Added +1.1m |
| PHARVARIS N V PHVS | $25.3m1.96% | Added +461.1k |
| FORMA THERAPEUTICS HLDGS INC SHS | $21.9m1.70% | Reduced -896.1k |
| HORIZON THERAPEUTICS PUB L HZNP | $21.3m1.66% | Added +167.5k |
| TANGO THERAPEUTICS INC TNGX | $20.4m1.58% | Reduced -391.3k |
| MIRATI THERAPEUTICS INC MRTX | $20.1m1.56% | Added +250.0k |
| AXONICS INC AXNX | $18.3m1.42% | Unchanged |
| KARUNA THERAPEUTICS INC COM | $15.8m1.23% | Reduced -25.0k |
| CYTOKINETICS INC CYTK | $15.7m1.22% | Unchanged |
| INTRA-CELLULAR THERAPIES INC ITCI | $15.7m1.22% | Added +125.0k |
| VECTIVBIO HLDG AG ORD SHS | $15.3m1.19% | Added +761.9k |
| GREENLIGHT BIOSCIENCS HLDS P COMMON STOCK | $15.2m1.18% | Added +250.0k |
| STOKE THERAPEUTICS INC STOK | $14.4m1.11% | Unchanged |
| CENTESSA PHARMACEUTICALS PLC SPONSORED ADS | $14.3m1.11% | Added +437.4k |
| BRIDGEBIO PHARMA INC BBIO | $13.3m1.03% | Reduced -99.7k |
| RAIN ONCOLOGY INC COM | $12.9m1.00% | Unchanged |
| IMMUNEERING CORP IMRX | $12.4m0.96% | Reduced -16.4k |
| ROCKET PHARMACEUTICALS INC RCKT | $12.0m0.93% | Unchanged |
| SPRINGWORKS THERAPEUTICS INC SWTX | $11.7m0.91% | New |
| ATEA PHARMACEUTICALS INC AVIR | $11.0m0.85% | Unchanged |
| VERVE THERAPEUTICS INC COM | $10.7m0.83% | Unchanged |
| VIRIDIAN THERAPEUTICS INC VRDN | $10.2m0.79% | Reduced -122.5k |
| KEZAR LIFE SCIENCES INC COM | $9.9m0.77% | New |
| VENTYX BIOSCIENCES INC VTYX | $9.5m0.74% | Reduced -4.7k |
| OLEMA PHARMACEUTICALS INC OLMA | $8.5m0.66% | Unchanged |
| AXSOME THERAPEUTICS INC AXSM | $7.9m0.61% | New |
| LONGBOARD PHARMACEUTICALS IN COM | $7.0m0.54% | Unchanged |
| COGENT BIOSCIENCES INC COGT | $6.8m0.52% | New |
| AMBRX BIOPHARMA INC SPONSORED ADS | $6.6m0.51% | Unchanged |
| GH RESEARCH PLC GHRS | $6.1m0.47% | Unchanged |
| BIOATLA INC BCAB | $5.8m0.45% | Unchanged |
| ALX ONCOLOGY HLDGS INC ALXO | $5.8m0.45% | Unchanged |
| CELLDEX THERAPEUTICS INC NEW CLDX | $5.4m0.42% | New |
| TYRA BIOSCIENCES INC TYRA | $5.3m0.41% | Reduced -13.4k |
| TALARIS THERAPEUTICS INC COM | $5.3m0.41% | Unchanged |
| ASCENDIS PHARMA A/S SPONSORED ADR | $4.6m0.36% | Unchanged |
| PLIANT THERAPEUTICS INC PLRX | $3.9m0.30% | Unchanged |
| AKERO THERAPEUTICS INC AKRO | $3.8m0.30% | Unchanged |
| ICOSAVAX INC COM | $3.7m0.29% | Added +225.0k |
| ELEDON PHARMACEUTICALS INC ELDN | $3.2m0.25% | Unchanged |
| ELEVATION ONCOLOGY INC COM | $2.8m0.22% | Added +3 |
| KEROS THERAPEUTICS INC KROS | $2.8m0.21% | Unchanged |
| Y-MABS THERAPEUTICS INC YMAB | $2.3m0.18% | Unchanged |
| AKOUOS INC COM | $1.9m0.14% | Unchanged |
| GALECTO INC GLTO | $1.8m0.14% | Unchanged |
| GOSSAMER BIO INC GOSS | $1.7m0.13% | Unchanged |
| PYXIS ONCOLOGY INC PYXS | $1.6m0.12% | Unchanged |
| VIGIL NEUROSCIENCE INC VIGL | $1.6m0.12% | Unchanged |
| CABALETTA BIO INC CABA | $1.2m0.09% | Unchanged |
| MEIRAGTX HLDGS PLC MGTX | $1.1m0.09% | Unchanged |
| AUTOLUS THERAPEUTICS PLC AUTL | $1.1m0.09% | Unchanged |
| CHEMOMAB THERAPEUTICS LTD SPONSORED ADS | $1.1m0.08% | Unchanged |
| HARPOON THERAPEUTICS INC COM | $1.0m0.08% | Unchanged |
| ANAPTYSBIO INC ANAB | $1.0m0.08% | Unchanged |
| RENOVACOR INC COM | $1.0m0.08% | Unchanged |
| GELESIS HLDGS INC GLSHQ | $970.0k0.08% | Unchanged |
| ASTRIA THERAPEUTICS INC CATB | $900.0k0.07% | Unchanged |
| ATRECA INC BCEL | $571.0k0.04% | Reduced -480.9k |
| GRAPHITE BIO INC GRPH | $549.0k0.04% | Reduced -3.6k |
| IMV INC COM | $155.0k0.01% | Unchanged |
| ORCHARD THERAPEUTICS PLC ORTX | $150.0k0.01% | Unchanged |
| X4 PHARMACEUTICALS INC COM | $100.0k0.01% | Unchanged |
Sold out since Q1 2022
| Security | Value then |
|---|---|
| HELIX ACQUISITION CORP MLTX | $33.3m3.3m shares |
| IGM BIOSCIENCES INC IGMS | $10.8m402.2k shares |
| PRAXIS PRECISION MEDICINES I | $7.7m752.4k shares |
| BEAM THERAPEUTICS INC BEAM | $5.2m90.0k shares |
| ITEOS THERAPEUTICS INC ITOS | $3.2m100.0k shares |
| PRECISION BIOSCIENCES INC | $1.1m346.5k shares |
Options (notional value)
| Underlying | Notional | Change |
|---|---|---|
| SPDR SER TR XBI · Call | $33.4m450.0k shares | New |
Stakes above 5%
Companies where this manager has reported owning more than 5% of a class of shares, on Schedule 13D (may seek influence) or 13G (passive): its latest filing for each, from 19 Dec 2024 on.
| Company | Stake |
|---|---|
| CORBUS PHARMACEUTICALS HLDGS CRBP · 13G · filed 2025-12-15 | 13.4%≈ $22.0m |
| IBIO INC IBIO · 13G · filed 2026-08-14 | 10.0%≈ $9.0m |
| QUINCE THERAPEUTICS INC IRLA · 13G · filed 2026-08-14 | 10.0%≈ $2.0m |
| BRIGHT MINDS BIOSCIENCES INC DRUG · 13G · filed 2026-08-14 | 9.2%≈ $32.0m |
| EYEPOINT PHARMACEUTICALS INC EYPT · 13G · filed 2026-08-14 | 8.3%≈ $100.1m |
| CARGO THERAPEUTICS INC 13G · filed 2025-05-15 | 7.3% |
| ADLAI NORTYE LTD ANL · 13G · filed 2026-08-14 | 6.8% |
| CABALETTA BIO INC CABA · 13G · filed 2026-08-14 | 6.0%≈ $31.1m |
| RAPPORT THERAPEUTICS INC RAPP · 13G · filed 2026-08-14 | 5.6%≈ $110.7m |
| BIOAGE LABS INC BIOA · 13G · filed 2026-08-14 | 5.4%≈ $58.6m |
| AGOMAB THERAPEUTICS NV AGMB · 13G · filed 2026-05-15 | 5.0% |